Your browser doesn't support javascript.
loading
Consolidation with 90 Yttrium-ibritumomab tiuxetan after bendamustine and rituximab for relapsed follicular lymphoma.
Miura, Katsuhiro; Tsujimura, Hideki; Masaki, Yasufumi; Iino, Masaki; Takizawa, Jun; Maeda, Yoshinobu; Yamamoto, Kazuhiko; Tamura, Shinobu; Yoshida, Akiyo; Yagi, Hideo; Yoshida, Isao; Kitazume, Koichi; Masunari, Taro; Choi, Ilseung; Kakinoki, Yasutaka; Suzuki, Ritsuro; Yoshino, Tadashi; Nakamura, Shigeo; Hatta, Yoshihiro; Yoshida, Takashi; Kanno, Masatoshi.
Afiliación
  • Miura K; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Tsujimura H; Division of Medical Oncology, Chiba Cancer Center, Chiba, Japan.
  • Masaki Y; Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan.
  • Iino M; Department of Medical Oncology, Yamanashi Prefectural Central Hospital, Kofu, Japan.
  • Takizawa J; Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan.
  • Maeda Y; Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Yamamoto K; Department of Hematology, Okayama City Hospital, Okayama, Japan.
  • Tamura S; Department of Hematology/Oncology, Kinan Hospital, Tanabe, Japan.
  • Yoshida A; Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan.
  • Yagi H; Department of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
  • Yoshida I; Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Kitazume K; Department of Hematology, Showa General Hospital, Tokyo, Japan.
  • Masunari T; Department of Infectious Diseases, Chugoku Central Hospital, Fukuyama, Japan.
  • Choi I; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Kakinoki Y; Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan.
  • Suzuki R; Department of Oncology/Hematology, Innovative Cancer Center, Shimane University Hospital, Izumo, Japan.
  • Yoshino T; Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Nakamura S; Department of Pathology and Biological Response, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Hatta Y; Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Yoshida T; Member, Society of Lymphoma Treatment in Japan, Kashihara, Japan.
  • Kanno M; Oncology Center, Nara Medical University Hospital, Kashihara, Japan.
Hematol Oncol ; 39(1): 51-59, 2021 Feb.
Article en En | MEDLINE | ID: mdl-32978820
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Folicular / Quimioterapia de Consolidación Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma Folicular / Quimioterapia de Consolidación Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Japón